AbbVie Candidate in Pivotal Study - Analyst Blog NASDAQ AbbVie and Biogen are developing daclizumab for relapsing remitting multiple sclerosis (regulatory applications slated for late 2014). AbbVie's Duopa is under review in the U.S. for advanced Parkinson's disease. Meanwhile, veliparib is in another phase ... |
